Fang et al. (2021) found that helenalin inhibits hepatic stellate cell activation by inhibiting miR-200a-mediated PI3K/Akt and NF-κB pathways, thus it can be used as a potential drug for the treatment of liver fibrosis. This evidence concerns the gene NFKB1 and Hepatic fibrosis.